4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
3 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
4 - Ainos, Inc. (0001014763) (Issuer)
Taiwan regulatory approval for the trial expected in Q1 2025Remains committed to a capital-efficient business strategySAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments.Th
IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.: N202408042), for its clinical trial of VELDONA® in treating Sjö
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests.Ainos management team views this matt
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed PatentsSecures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbo
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndromeBurgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights
Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robotsVELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it continues to push the boundaries of global smart healthcare and immunotherapy innovation. With its AI Nose and VELDONA® low-dose
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA)SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration (
Sjogren's Syndrome is a rare autoimmune disease with limited treatment optionsPrior U.S. Phase 3 data demonstrated benefitsSAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's upcoming clinical study for VELDONA® in treating primary Sjogren's syndrome, targeted to begin in December 2024 in Taiwan.The report emphasizes Ainos' capital-efficient strategy in conducting clinical trials within Taiwan. Foll
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretionAinos aims to complete all regulatory approvals for the study in Q4 2024SAN DIEGO, CA / ACCESSWIRE / September 23, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that it plans to conduct a Taiwan clinical study for very low-dose interferon alpha (VELDONA) on treating Sjögren's syndrome at Taipei Medical University-Shuang Ho Hospital. A total of eight clinical trials have been conducted in the U.S. by the Company to eval
10-Q - Ainos, Inc. (0001014763) (Filer)
8-K - Ainos, Inc. (0001014763) (Filer)
8-K - Ainos, Inc. (0001014763) (Filer)
DEFA14A - Ainos, Inc. (0001014763) (Filer)
DEF 14A - Ainos, Inc. (0001014763) (Filer)
8-K - Ainos, Inc. (0001014763) (Filer)
8-K - Ainos, Inc. (0001014763) (Filer)
10-Q - Ainos, Inc. (0001014763) (Filer)
S-8 POS - Ainos, Inc. (0001014763) (Filer)
S-8 - Ainos, Inc. (0001014763) (Filer)
SC 13D - Ainos, Inc. (0001014763) (Subject)
SC 13D/A - Ainos, Inc. (0001014763) (Subject)
SC 13D/A - Ainos, Inc. (0001014763) (Filed by)
SC 13D/A - Ainos, Inc. (0001014763) (Filed by)
SC 13D/A - Ainos, Inc. (0001014763) (Subject)
SC 13D/A - Ainos, Inc. (0001014763) (Subject)
SC 13D/A - Ainos, Inc. (0001014763) (Subject)
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside
Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress
Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and InabataSAN DIEGO, CA / ACCESSWIRE / March 8, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the year ended December 31, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ain
Product Cycle Transition Approaches its Final StagesNew Product Line Expected to Gain Momentum in the Fourth QuarterSAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the third quarter ended September 30, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "During the third quarter of 2023, we took key steps towards establishing new revenue stream
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the second quarter ended June 30, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The second quarter of 2023 was a transi
Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologiesStrategic pivot is underpinned by Ainos' diversified product pipelineSAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023.Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Th
Revenues increased by 3,832% year over yearDebt ratio improved to 7% from 75% at year-end 2021SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the fourth quarter and full year ended December 31, 2022.Fourth Quarter 2022 Financial HighlightsRevenues were US$1,038,025 in the fourth quarter of 2022, up 3,832% year over year.Gross profit was US$459,815, up 2,668% year over year, representing a gross margin of 44.3% in the four
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease c
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. Sharps Technology (NASDAQ:STSS) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. Autonomix Medical (NASDAQ:AMIX) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. Akso Health Group (NASDAQ:AHG) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. Conduit Pharmaceuticals (NASDAQ:CDT) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 mill
Gainers Ainos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. Molecular Partners (NASDAQ:MO
Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the initiation of a clinical study for a new potential VELDONA®-based drug for pet disease. The study is aimed at evaluating the clinical efficacy of low-dose oral interferons in treating feline chronic gingivostomatitis ("FCGS"), a serious and chronic painful oral disease characterized by inflammation or abnormal proliferation in the oral cavity.
- SEC Filing
- SEC Filing
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. Dyadic International (NASDAQ:DYAI) stock rose 21.73% to $1.68. The company's market cap stands at $48.4 million. Mesoblast (NASDAQ:MESO) shares rose 19.53% to $2.57. The company's market cap stands at $260.8 million. Aprea Therapeutics (NASDAQ:APRE) stock moved upwards by 15.28% to $8.22. The market value of their outstanding shares is at $30.7 million. Talphera (NASDAQ:TLPH) stock increased by 13.77% to $1.28. The market value of their outstanding shares is at $21.7 million. The company's, Q4 earnings came out 3 days ago.
Full Year 2023 Financial ResultsRevenuesRevenues were US$122,112, compared to US$3,519,627 in the full year of 2022, reflecting a decrease in selling price and sales volume of the Company's COVID-19 Antigen Rapid Test Kits attributable to the slowdown of COVID-19 infections in Taiwan.Cost of RevenuesCost of revenues was US$375,845 in the full year of 2023, compared with U$$2,114,284 in the same period of 2022. The decrease was primarily attributable to a decline in sales volume, partially offset by recognition of inventory loss.Gross ProfitIn the full year of 2023, gross profit was negative US$253,733, compared with a positive gross profit of US$1,405,343 a year ago, driven by declines in sa